The increasing use of high-dose chemotherapy with autologous hematopoietic transplantation for the treatment of solid malignancies has raised concern about the role of tumor cells contaminating the grafts. Minimal residual disease (MRD) in autologous grafts has became a dynamic and intensively studied field in oncology. This review discusses the current status of MRD in breast cancer autografts and presents existing data on detection methodology, clinical relevance, biologic characteristics and purging techniques.
Introduction
Breast cancer is the most common solid tumor for which high-dose chemotherapy (HDC) and autologous hematopoietic transplantation (AHT) is performed [1] . Initial results from clinical trials using high-dose chemotherapy protocols in breast cancer patients have suggested an increased therapeutic benefit compared to conventional regimens, with potentially improved response rates and better survival [2, 3] . However, it is likely that most patients, especially those treated for metastatic disease, will eventually relapse [1] . The source of relapse in the autologous transplantation setting could either be minimal residual disease (MRD) in the patient that survived the high-dose chemotherapy, or residual tumor cells within the hematopoietic harvest transplanted to restore the hematopoiesis following high-dose chemotherapy. This review centers around contaminating tumor cells in autografts from breast cancer patients. In addition, state-of-the-art techniques developed to detect and to eliminate MRD present in autologous transplants in order to improve treatment outcome will be presented.
Detection methods of minimal disease in hematopoietic harvests
Over the last several years, immunostaining of epithelial-tissue specific components has become the standard method for detection of breast cancer cells in hematopoietic tissues [4] . Most studies recommend the use of monoclonal antibodies (MoAbs) against cytokeratins, which are integral components of the epithelial cytoskeleton, and discourage the use of MoAbs to epithelialspecific cell membrane proteins because of their frequent cross-reactivity with hematopoietic cells [5] . Because of the heterogeneity of antigen expression within and between different tumors and a possible down regulation of single cytokeratin components on micrometatstatic tumor cells, the use of broad-spectrum MoAbs is preferred [6] . Immunocytochemical staining (ICC) using the alkaline phosphatase anti-alkaline phosphatase method seems to be superior to immunofluorescence since the latter method does not permit adequate morphologic examination of the fluorescing cells, and does not provide permanent record since the staining fades relatively quickly over time. Progress has been made in cell processing methods to avoid cell losses and ensure preservation of morphology by attaching cells to optimised precoated matrix [7] , and in the development of Fc-free Fab-antibody fragments that are directly conjugated to the preferred marker enzyme (e.g., alkaline phosphatase) without the need of secondary MoAbs [5] . Automated image analysis systems, which allow rapid identification of rare events in a high number of cells screened [8] , and tumor cell enrichment methods [9] have been developed to enhance the sensitivity of the ICC method. Flow cytometry has also been reported to be a sensitive and specific method to detect contaminating epithelial cancer cells but has been less widely studied [10] .
The reverse transcriptase polymerase chain reaction (RT-PCR) method for the detection of epithelial tumor cells based on cytokeratin 19 (CK19) expression has a greater sensitivity than the ICC analysis [11] , but the illegitimate transcription of CK19 by hematopoietic cells can lead to loss of specifity [12] . Immunocytochemistry and RT-PCR are currently being compared in breast cancer patient harvests in a multicenter study sponsored by the International Society for Hematotherapy and Graft Engineering (ISHAGE) [13] . It has been suggested that ICC should be employed to demonstrate the contamination of a harvest product and CK19 RT-PCR to confirm the negative results from the immunocytochemical analysis [14] . A consensus has been formulated that for statistical considerations a RT-PCR assay on an individual patient may have to be run at least five times to ensure that it is truly negative [5] . Recently, a novel epidermal growth factor receptor specific RT-PCR has been described for the detection of low numbers of breast cancer cells in apheresis products [15] . In addition, further discrepancies between RT-PCR and ICC detection may be due to heterogeneity in the tumor cell population.
Cell culture techniques in combination with ICC have also been employed to detect tumor cells. In a long-term (eight weeks) culture method used by Sharp et al. [16, 17] , the culture amplified both the relative and the absolute number of tumor cells present. By subjecting the harvest product to a shorter period (seven to 14 days) of in vitro culture before the ICC analysis, we and others increased the detection limit of tumor cells in this assay (unpublished and [18] ). This occurs because the hematopoietic cells are lost from the cultures and (some of) the epithelial cells survive, resulting in an increase of the tumor cell incidence in the specimen studied. It seems that culture combined with ICC is as specific as ICC alone and at least as sensitive as the RT-PCR technique [13] . Ross et al. [19] employed a short-term clonal culture method in semisolid medium which detects solid tumor cells by inducing their clonogenic growth. A limitation of these culture-mediated detection methods is the long time (e.g., approximately 14 days) between initiation and readout which is critical when selecting the autograft with the lowest potential of contributing to relapse, since within the culture period most of the patients will already have received the HDC and the subsequent AHT. This problem might be solved by identification of specific immune markers of clonogenic tumor cells, or other malignant cell subpopulations which may indicate their potential of regrowth in the transplanted patient.
Clinical significance of minimal residual disease in hematopoietic harvests
A growing body of evidence in a number of diseases indicates that tumor cells within the autograft may contribute to posttransplant relapse. This has been directly demonstrated in childhood acute myelogenous leukemia (AML) [20] , neuroblastoma [21] and chronic myelogenous leukemia (CML) [22] by gene marking studies, in which the gene marked infused tumor cells present in the hematopoietic harvests were traced to sites of disease relapse. Niederwie et al. [23] reported transmission of AML through an allogeneic bone marrow transplantation into a recipient with CML and concluded that the infusion of bone marrow contaminated with cancer cells can lead to the development of the transplanted malignancy in the new host. Indirect evidence indicating that the cause of relapse in autotransplants is related to transfer of occult cancer cells has been suggested by studies in lymphoma [24] and AML [25, 26] patients in which successful purging of the autograft has reduced the rate of relapse after the transplantation. Additionally, Sharp et al. [27] in a retrospective study in lymphoma patients recently showed that detectable contamination of autografts may predict subsequent relapse.
The clinical relevance of minimal disease in hematopoetic transplants in patients with breast cancer is up to now unclear. Limited studies of retrospective clinical trials comparing the posttransplant outcome in the absence or presence of contaminating tumor cells have been reported, most of them in an abstract form [28] [29] [30] [31] [32] [33] [34] [35] [36] . Some studies suggest that metastatic breast cancer patients with immuncytochemically detectable tumor cell contamination in the graft have a trend towards increased relapse rates and decreased overall survival [28] [29] [30] , yet others have not found such associations [31] . Reports on breast cancer patients with earlier stages of disease suggest a more clear association between the degree of tumor cell contamination in the graft and adverse clinical outcome [32, 33, 35, 36] . Since tumor progression in autotransplanted patients with metastatic breast cancer is rapid and with current treatment regimens only approximately 20% of patients experience long-term (three years) disease free survival [1] , the outcome of patients with earlier stages of disease is likely to be more informative as to the role of contamination of the autograft. Kessinger et al. [34] reported a strong correlation between contamination of the bone marrow graft and survival in breast cancer patients. Although it was not reported whether the patients had received HDC followed by AHT for metastatic disease or in an adjuvant setting, it is noteworthy that tumor cell detection in the graft was performed using a culture step. Probably it is not the presence but the biologic function of the occult tumor cells in the graft which is of clinical concern, underscoring the need for further study of the biological behaviour of these cells.
When analyzing data that correlate tumor cell contamination of the autograft and posttransplant relapse, it is difficult to ascertain whether the contaminating tumor cells lead to the development of the relapse or their detection denotes only a systemic tumor burden or a particularly aggressive form of disease. An ongoing gene marking study in metastatic breast cancer patients may answer these questions [37] . Another approach to determine the role of contaminating tumor cells in breast cancer and to overcome ethical problems encountered with gene marking studies which may intentionally redeliver tumor cells into the patients is the clinical use of highly efficient purging strategies in autologous transplants. Results of randomized trials comparing purged with unpurged hematopoietic transplantats in breast cancer are still missing.
Biology of contaminating breast cancer cells
A number of studies have aimed at determining the biologic characteristics of the micrometastastic breast cancer cells within bone marrow. The currently available information suggests that these cells differ in many issues from the majority of the primary tumor cells. Micrometastatic cells frequently show a down regulation of the HLA class I molecules [38] , neo-expression of the intercellular adhesion molecule-1 [39] and expression of the erbB2 oncogene [40] . A suggestion has been made that these phenotypic characteristics may preferentially support the survival and/or outgrowth of these cells in the bone marrow environment. The majority of the contaminating breast cancer cells appear to be in the Go phase of the cell cycle, as judged by the absence of expression of the nuclear proliferation markers Ki-67 and pl20 [40] . This supports the theory that these cells remain in dormancy. Under special culture conditions they may escape their dormant status and may proliferate as demonstrated by long-term [16, 17, 41] and short-term [19] culture techniques. However, the in vitro growth potential of these cells remains heterogenous [41] and their growth requirements are up to now poorly understood. They seem to interact symbiotically with bone marrow cells [13, 42] , and some investigators suggest the existence in the bone marrow environment of ligands and growth factors which promote tumor cell survival and proliferation [13] . The nature of such molecules is only beginning to be determined. The observation that cultured micrometastatic breast cancer cells reinfused into severe combined immunodeficient (SCID) mice disseminate into the bone marrow supports the theory that these cells associate preferentially with bone marrow stromal cells and suggest an organ-specific homing affinity [41] .
The biological characteristics of breast cancer cells contaminating apheresis harvests of mobilized blood are less well studied. A hypothesis has been made that the origin of these cells are bone marrow micrometastases from which the cells are recruited concomitantly with the hematopoietic stem cells during the peripheral blood stem cell (PBSC) priming [43] . The currently available information suggests that the tumor cells may be more frequent in the mobilized blood compared to nonmobilized blood [44, 45] and therefore tumor cells may be mobilized from bone marrow or sites other than bone marrow (or sites in bone marrow others than those sampled to detect marrow tumor) into the blood. However, in this circumstance, it is unclear if cytokines administrated during mobilization contribute to the tumor cell contamination of the blood by stimulating tumor cell growth [46] . The relative contribution of chemotherapy and cytokines administrated for the PBSC priming to tumor cell mobilization remains a matter of debate [44, 47] , however the incidence of tumor contamination in the peripheral blood stem cell products increases with the number of apheresis [48] . Like the bone marrow contaminating cells, circulating breast cancer cells detected in the apheresis specimens appear to be viable and capable of clonogenic growth in vitro [19, 44] . Studies comparing the biologic aggressiveness of mobilized tumor cells in PBSC specimens and of bone marrow-derived tumor cells are missing. These data might be essential to selecting among various available apheresis fractions the autograft with the lowest transplanted malignant potential.
Purging techniques in breast cancer
Considering that residual tumor cells within the autograft may contribute to posttransplant relapse, tumor cell depletion procedures (i.e., purging) appear to be highly desirable. Since threshold numbers for tumor cells within a transplant have not been clinically denned, current concepts aim at maximal tumor cell elimination. In vivo purging by dose intensive chemotherapy prior to stem cell mobilization may favor the harvest of a tumorcell free transplant [33] , however maximally effective purging may require ex vivo manipulation. It appears unlikely that stem cell selection procedures which separate CD34+ hematopoietic cells will fully deplete the graft from breast cancer cells. The reported clinical trials using currently available CD34+ selection technology have not yet achieved consistent preparations of greater A. In vivo purging.
• Chemotherapy.
B. Ex vivo purging.
• Depletion strategies:
-physical systems (lectins, ether lipids, hyperthermia, depth filtration, density gradient); -monoclonal antibodies (complement, immunomagnetic separation, immunotoxin); -drug treatments (4-hydroperoxycyclophosphamide, mafosfamide); -gene therapy (adenoviral vectors).
• Stem cell selection:
-CD34+ blood progenitor cells (BPC); -ex vivo expansion of CD34+ BPC.
than 90% purity of CD34+ cells with a consequent about 2 log predicted depletion of breast cancer cells [49] .
Contaminating breast cancer cells have already been detected in positively selected CD34+ fraction from bone marrow [49] and mobilized peripheral blood ( [15] , and own unpublished results). For further purging steps in addition to the positive selection of CD34+ cells, depletion techniques which specifically target and eliminate malignant cells within the graft can be used. A number of possible procedures have been described. Some investigators have attempted depletion of the breast cancer cells by physical procedures like density gradient separations [50] , lectins [51] , ether lipids and subsequent cryopreservation [52] , hyperthermia [53] , depth filtration [54] , or drug treatments [55, 56] . Recently, adenoviral vectors in combination with toxin genes {Pseudomonas exotoxin) or wild-type p53 protein have been also proposed for epithelial cells purging [57, 58] . The potential toxicity of these procedures to the normal hematopoietic cells, which may result in impaired hematopoietic recovery after transplantation, has led to the development of monoclonal antibody based purging techniques. For the antibody depletion systems, the antibodies selected target epithelial or breast cancer antigens, are non-crossreactive with hematopoietic cells and are combined with magnetic microspheres [59, 60] or toxins [60] [61] [62] [63] [64] to lyse or eliminate the antibody-bound cells. Various studies using such immunologic purging techniques, for example immunotoxins, suggest a high level of tumor cell depletion. However, these results must be interpreted with caution since the reported purging efficacies refer only to removal of cell lines from model systems. These exogenously added culture-adapted cells may differ in many aspects from the ultimate target cells which the purging procedure is being designed to eliminate, such as lack of expression of the target antigen, low antigen expression density, immunphenotype heterogenity within the cell populations and proliferation status. Ex vivo expansion of CD34+ hematopoietic cells has been proposed as an alternative, or additional, tumor cell purging strategy by reducing the volume of blood processed from the patient and by creating conditions adverse for survival and growth of the potentially contaminating tumor cells but spurring hematopoietic cell survival, expansion and development [65] [66] [67] [68] [69] . The influence of ex vivo expansion parameters -culture medium, cytokines, hematopoietic cells -on the ex vivo tumor cell survival, growth and clonogenicity are currently being defined. Whereas hematopoietic growth factors do not influence survival and proliferation of primary breast cancer cells, we found a strong tumor-cell suppressive effect when using serum-free preparations or when TGF-pi was added to the cultures [70] . This technology may be combined with other purging techniques, like molecular depletion by immunotoxins [71] , creating highly efficient purging strategies. Assessment of the clinical value of ex vivo tumor depletion methods awaits the results of clinical trials.
Conclusions
Minimal residual disease in autografts has become a dynamic and intensively studied field in oncology. A number of investigators are working on the development of techniques to detect contaminating tumor cells, to understand their biology and their clinical relevance, and to eliminate them from autotransplants in order to improve the outcome in patients. Researchers must now turn their attention to demonstrate and establish the clinical benefits of such procedures.
